The immune response: The afferent arm

Clinical Orthopaedics and Related Research

Volumn 326, Issue , 1996, Pages 11-24

  Czitrom, Andrei A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; ANTIGEN; B7 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR;

ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; AUTOIMMUNITY; BONE TRANSPLANTATION; CLONAL ANERGY; CONFERENCE PAPER; HISTOCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MUSCULOSKELETAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0029872271     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/00003086-199605000-00003     Document Type: Conference Paper

References (115)

1. Aosai F, Oehlen C, Ljunggren HG, et al: Different types of allospecific CTL clones identified by their ability to recognize peptide loading-defective target cells. Eur J Immunol 21:2767-2774, 1991.
2. Ardavin C, Wu L, Li CL, Shortman K: Thymic dendritic cells and T-cells develop simultaneously in the thymus from a common precursor population. Nature 362:761-763, 1993.
3. Auchincloss Jr H, Lee R, Shea S, et al: The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci 90:3373-3377, 1993.
4. Batchelor JR: Transplant immunology. Transplant Proc 26:1875-1876, 1994.
5. Benichou G, Takizawa AP, Olson AC, McMillan M, Sercarz EE: Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med 175:305-308, 1992.
6. Bevan MJ: Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 143:1283-1287, 1976.
7. Bretcher P: The two-signal model of lymphocyte activation twenty-one years later. Immunol Today 13:74-76, 1992.
8. Bretcher P, Cohn M: A theory of self-nonself discrimination. Science 169:1042-1049, 1970.
9. Breur-Viesendorp BS, Ivanyi P: Self-restricted primary human histocompatibility leukocyte antigen (HLA) - specific cytotoxic T lymphocytes. Int Immunol 5:103-107, 1993.
10. Burkly LC, Lo D, Kanagawa O, Brinster RL, Flavell RA: T-cell tolerance by clonal anergy in transgenic mice with nonlymphoid expression of MHC class II I-E. Nature 342:564-566, 1989.
11. Champion BR, Sell S, Poole AR: Immunity to homologous collagen and cartilage proteoglycans in rabbits. Immunology 48:605-616, 1983.
12. Chicz RM, Urban RG, Gorga JC, et al: Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178:27-47, 1993.
13. Chien Y, Davis MM: How alpha beta T-cell receptors 'see' peptide/MHC complexes. Immunol Today 14:597-602, 1993.
14. Crumpacker DB, Alexander J, Cresswell P, Engelhard V: Role of endogenous peptides in murine allogeneic cytotoxic cell responses assessed using transfectants of the antigen-processing mutant 174xCEM T2. J Immunol 148:3004-3011, 1992.
15. Czitrom AA: Bone Transplantation, Passenger Cells and the Major Histocompatibility Complex. In Aebi M, Regazzoni P (eds). Bone Transplantation. Berlin, Springer-Verlag 103-110, 1989.
16. Czitrom AA: Immunology of Bone and Cartilage Allografts. In Czitrom AA, Gross AE (eds). Allografts in Orthopaedic Practice. Baltimore, Williams and Wilkins 15-25, 1992.
17. Czitrom AA: Biology of Bone Grafting and Principles of Bone Banking. In Weinstein SL (ed). The Pediatric Spine: Principles and Practice. New York, Raven Press 1285-1298, 1994.
18. Czitrom AA, Axelrod T, Fernandes B: Antigen presenting cells and bone allotransplantation. Clin Orthop 197:27-31, 1985.
19. Czitrom AA, Axelrod T, Fernandes B: Granulocyte precursors are the principal cells in bone marrow that stimulate allospecific cytolytic T-lymphocyte responses. Immunology 64:655-660, 1988.
20. Czitrom AA, Gascoigne NRJ, Edwards S, Waterfield DJ: Induction of minor alloantigen-specific T cell subsets in vivo: Recognition of processed antigen by helper but not by cytotoxic T cell precursors. J Immunol 133:33-39, 1984.
21. Czitrom AA, Katz DR, Sunshine GH: Alloreactive cytotoxic T lymphocyte responses to H-2 products on purified accessory. Immunology 45:553-560, 1982.
22. Czitrom AA, Keating S, Gross AE: The viability of articular cartilage in fresh osteochondral allografts after clinical transplantation. J Bone Joint Surg 72A:574-581, 1990.
23. Czitrom AA, Langer F, McKee N, Gross AE: Bone and cartilage allotransplantation. A review of 14 years of research and clinical studies. Clin Orthop 208:141-145, 1986.
24. Czitrom AA, Sunshine GH, Reme T, et al: Stimulator cells requirements for allospecific T cell subsets: Specialized accessory cells are required to activate helper but not cytotoxic T lymphocyte precursors. J Immunol 130:546-550, 1983.
25. Dalchau R, Fangmann J, Fahre JW: Allorecognition of isolated, denatured chains of class I and class II major histocompatibility complex molecules. Evidence for an important role for indirect allorecognition in transplantation. Eur J Immunol 22:669-677, 1992.
26. Dallman MJ, Shiho O, Page TH, Wood KJ, Morris PJ: Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 173:79-87, 1991.
27. Damle NK, Klussman K, Leytze G, Linsley PS: Proliferation of human T lymphocytes induced with superantigens is not dependent on costimulation by the CD-28 counter-receptor B7. J Immunol 150:726-735, 1993.
28. Davis MM, Bjorkman PJ: T-cell antigen receptor genes and T-cell recognition. Nature 334:395-402, 1988.
29. Doyle C, Strominger JL: Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 330:256-259, 1987.
30. Eckels DD: Alloreactivity: Allogeneic presentation of endogenous peptides or direct recognition of MHC polymorphism. Tissue Antigens 35:49-55, 1990.
31. Elliott TJ, Eisen HN: Cytotoxic T lymphocytes recognize a reconstituted class I histocompatibility antigen (HLA-A2) as an allogeneic target molecule. Proc Natl Acad Sci USA 87:5213-5217, 1990.
32. Esses SI, Halloran PF: Donor marrow-derived cells as immunogens and targets for the immune response to bone and skin allografts. Transplantation 35:169-174, 1983.
33. Evavold BD, Sloan-Lancaster J, Allen PM: Tickling the TCR: Selective T-cell functions stimulated by altered peptide ligands. Immunol Today 14:602-609, 1993.
34. Fangmann J, Dalchau R, Fabre JW: Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med 175:1521-1529, 1992.
35. Friedlaender GE, Strong DM, Sell KW: Studies on the antigenicity of bone. II. Donor specific anti-HLA antibodies in human recipients of freeze-dried allografts. J Bone Joint Surg 66A:107-112, 1984.
36. Gay D, Maddon P, Sekaly R, et al: Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen. Nature 328:626-629, 1987.
37. Gertzbein SD, Tait JD, Devlin SR, Argue S: The antigenicity of chondrocytes. Immunology 33:141-145, 1977.
38. Gilbert KM, Hoang KD, Weigle WO: Th1 and Th2 clones differ in their response to a tolerogenic signal. J Immunol 144:2063-2071, 1990.
39. Goodnow CC, Brink R, Adams E: Breakdown of self-tolerance in anergic B lymphocytes. Nature 352:532-536, 1991.
40. Guerder S, Matzinger P: Activation versus tolerance: A decision made by T helper cells. Cold Spring Harb Symp Quant Biol 54:799-805, 1989.
41. Helbert MR, L'age-Stehr J, Mitchison NA: Antigen presentation, loss of immunological memory and AIDS. Immunol Today 14:340-344, 1993.
42. Horowitz MC, Friedlaender GE: Induction of specific T-cell responsiveness to allogeneic bone. J Bone Joint Surg 73A:1157-1168, 1991.
43. Ibrahim MAA, Chain BM, Katz DR: The injured cell: The role of the dendritic cell system as a receptor pathway. Immunol Today 16:181-186, 1995.
44. Inaba K, Inaba M, Naito M, Steinman RM: Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med 178:479-488, 1993.
45. Janeway CA: Ligands for the T-cell receptor: Hard times for avidity models. Immunol Today 16: 223-225, 1995.
46. Janeway CA, Dianzani U, Portholes P, et al: Cross-linking and conformational change in T-cell receptors: Role in activation and in repertoire selection. Cold Spring Harb Symp Quant Biol 54:657-666, 1989.
47. Jenkins MK: The role of cell division in the induction of clonal anergy. Immunol Today 13:69-73, 1992.
48. Jenkins MK, Mueller D, Schwartz RH, et al: Induction and maintenance of anergy in mature T cells. Adv Exp Med Biol 292:167-176, 1991.
49. Jonsson J, Boyce NW, Eichmann K: Immunoregulation through CD8 (Lyt-2): State of aggregation with the alpha/beta/CD3 T cell receptor controls interleukin 2-dependent T cell growth. Eur J Immunol 19:253-260, 1989.
50. Julius M, Maroun CR, Haughn L: Distinct roles for CD4 and CD8 as co-receptors in antigen receptor signaling. Immunol Today 14:177-183, 1993.
51. June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today 15:321-332, 1994.
52. June CH, Ledbetter JA, Linsley PS, Thompson CB: Role of the CD28 receptor in T-cell activation. Immunol Today 11:211-216, 1990.
53. Kappler JW, Roehm N, Marrack P: T cell tolerance by clonal elimination in the thymus. Cell 49:273-280, 1987.
54. Korngold R, Sprent J: Selection of cytotoxic T cell precursors specific for minor histocompatibility determinants. I. Negative selection across H-2 barriers induced with disrupted cells but not with glutaraldehyde-treated cells: Evidence of antigen processing. J Exp Med 151:314-327, 1980.
55. Lafferty KJ, Prowse SK, Simenovic CJ, Warren HS: Immunobiology of tissue transplantation: A return to the passenger leukocyte concept. Ann Rev Immunol 1:143-173, 1983.
56. Lafferty KJ, Woolnough J: The origin and mechanism of allograft rejection. Immunol Rev 35:231-262, 1977.
57. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldman M: Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 157:1434-1447, 1983.
58. Langer F, Czitrom A, Pritzker KP, Gross AE: The immunogenicity of fresh and frozen allogeneic bone. J Bone Joint Surg 57A:216-220, 1975.
59. Langer F, Gross AE: Immunogenicity of allograft articular cartilage. J Bone Joint Surg 56A:297-304 1974.
60. Larsen CP, Morris PJ, Austyn JM: Migration of dendritic leukocytes from cardiac allografts into host spleens: A novel pathway for initiation of rejection. J Exp Med 171:307-314, 1990.
61. Larsen CP, Steinman RM, Witmer MD, et al: Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 172:1483-1493, 1990.
62. Ledbetter JA, Gilliland LK, Schieven LS: The interaction of CD4 with CD3/Ti regulates tyrosine phosphorylation of substrates during T cell activation. Semin Immunol 2:99-106, 1990.
63. Linsley PS, Brady W, Urnes M, et al: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561-569, 1991.
64. Linsley PS, Ledbetter JA: The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11:191-212, 1993.
65. MacDonald H, Glasebrook A, Bron C, Kelso A, Cerottini JC: Clonal heterogeneity in the functional requirement for Lyt-2/3 molecules on cytolytic T lymphocytes (CTL): Possible implications for the affinity of CTL antigen receptors. Immunol Rev 68:89-115, 1982.
66. Matsui K, Boniface JJ, Reay PA, et al: Low affinity interaction of peptide-MHC complexes with T cell receptors. Science 254:1788-1791, 1991.
67. Mitchison NA, O'Malley C: Three-cell clusters of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response. Eur J Immunol 17: 1579-1583, 1987.
68. Moller E: Cell interactions and cytokines in transplantation immunity. Transplant Proc 27:24-27, 1995.
69. Morahan G, Allison J, Miller JFAP: Tolerance of class I histocompatibility antigens expressed extrathymically. Nature 339:622-624, 1989.
70. Mueller DL, Jenkins MK, Schwartz RH: Clonal expansion versus functional clonal inactivation: A costimulatory signaling pathway determines the outcome of T cell receptor occupancy. Annu Rev Immunol 7:445-480, 1989.
71. Muscolo DL, Caletti E, Schajovitz F, Araujo ES, Makino A: Tissue-typing in human massive allografts of frozen bone. J Bone Joint Surg 69A:583-595, 1987.
72. Muscolo DL, Kawai S, Ray RD: Cellular and humoral immune response analysis of bone allografted rats. J Bone Joint Surg 58A:826-832, 1976.
73. Nickoloff BJ, Mitra RS, Green J, et al: Accessory cell function of keratinocytes for superantigens. Dependence on lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. J Immunol 150:2148-2159, 1993.
74. Nickoloff BJ, Mitra RS, Lee K, et al: Discordant expression of CD28 ligands, BB-1, and B7 on keratinocytes in vitro and psoriatic cells in vivo. Am J Pathol 142:1029-1040, 1993.
75. Nickoloff BJ, Turka LA: Immunological functions of non-professional antigen presenting cells: New insights from studies of T-cell interactions with keratinocytes. Immunol Today 15:464-469, 1994.
76. Nossal GJV: Cellular mechanisms of immunologic tolerance. Annu Rev Immunol 1:33-62, 1983.
77. Olson CA, Williams LC, McLaughlin-Taylor E, McMillan M: Creation of H-2 class I epitopes using synthetic peptides: Recognition by alloreactive cytotoxic T lymphocytes. Proc Natl Acad Sci USA 86:1031-1035, 1989.
78. O'Rourke AM, Mescher MF: The roles of CD8 in cytotoxic T lymphocyte function. Immunol Today 14:183-188, 1993.
79. Owens T, Czitrom AA, Gascoigne NRJ, et al: The presentation of cell surface alloantigens to T cells. Immunobiology 168:189-201, 1984.
80. Racioppi L, Ronchese F, Matis LA, Germain RN: Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling. J Exp Med 77:1047-1060, 1993.
81. Rafii-Tabar E, Czitrom AA: Ontogeny of priming of cytotoxic T cells to minor alloantigens: The development of direct priming precedes that of cross-priming. Eur J Immunol 16:1025-1027, 1986.
82. Ramsdell F, Fowlkes BJ: Clonal deletion versus clonal anergy: The role of the thymus in inducing self tolerance. Science 248:1342-1348, 1990.
83. Rees MA, Rosenberg AS, Munitz TI, Singer A: In vivo induction of antigen-specific transplantation tolerance to Qa1a by exposure to alloantigen in the absence of T-cell help. Proc Natl Acad Sci USA 87:2765-2769, 1990.
84. Reis-e-Sousa C, Stahl PD, Austin JM: Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med 178:509-519, 1993.
85. Ron Y, Sprent J: T cell priming in vivo: A major role for B cells in presenting antigens to T cells in lymph nodes. J Immunol 138:2848-2856, 1987.
86. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109-1118, 1994.
87. Salter RD, Benjamin RJ, Wesley PK, et al: A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. Nature 345:41-46, 1990.
88. Sawyer GJ, Dalchau R, Fabre JW: Indirect T cell allorecognition: A cyclosporin A resistant pathway for T cell help for antibody production to donor MHC antigens. Transplant Immunol 1:77-81, 1993.
89. Sayegh MH, Watshinger B, Carpenter C: Mechanism of T cell recognition of alloantigen. Transplantation 57:1295-1302, 1994.
90. Schendel D, Reinhardt G, Nelson AJ, et al: Cytotoxic T lymphocytes show HLA-C-restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides. J Immunol 149:2406-2416, 1992.
91. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065-1068, 1992.
92. Sherwood RA, Brent L, Rayfield LS: Presentation of alloantigens by host cells. Eur J Immunol 16:569-574, 1986.
93. Shoskes DA, Wood KJ: Indirect presentation of MHC antigens in transplantation. Immunol Today 15:32-38, 1994.
94. Silvers WK, Kimura H, Desquenne-Clark L, Miyamoto M: Some new perspectives on transplantation immunity and tolerance. Immunol Today 8:185-190, 1987.
95. Speiser DE, Chvatko Y, Zikernagel RM, MacDonald HR: Distinct fates of self-specific T cells developing in irradiation bone marrow chimeras: Clonal deletion, clonal anergy, or in vitro responsiveness to self-MLs-1a controlled by hemopoietic cells in the thymus. J Exp Med 172:1305-1314, 1990.
96. Sprent J, Kosaka H, Gao EK, Surh CD, Webb S: Intrathymic and extrathymic tolerance in bone marrow chimeras. Immunol Rev 133:151-176, 1993.
97. + T Cells. Immunol Rev 117:213-234, 1990.
98. Sprent J, Webb S: Function and specificity of T cell subsets in the mouse. Adv Immunol 41:39-133, 1987.
99. Steinman RM, Gutchinov B, Witmer MD, Nussenzweig MC: Dendritic cells are the principal stimulators of the primary mixed leukocyte reaction in mice. J Exp Med 157:613-627, 1983.
100. Steinman RM, Witmer MD: Lymphoid dendritic cells are a potent stimulator of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA 75:5132-5136, 1978.
101. Stevenson S, Horowitz M: Current Concepts Review: The response to bone allografts. J Bone Joint Surg 74A:939-950, 1992.
102. Strong M: Immunological Responses in Human Recipients of Osseous and Osteochondral Allografts. Abstract Book of International Symposium on Bone and Soft Tissue Allografts, 29-30, Washington, D.C. April 28-30, 1995.
103. Sunshine GH, Katz DR, Czitrom AA: Heterogeneity of stimulator cells in the murine mixed leukocyte response. Eur J Immunol 12:9-15, 1982.
104. Sunshine GH, Katz DR, Feldmann M: Dendritic cells induce T cell proliferation to synthetic antigens under Ir gene control. J Exp Med 152:1817-1822, 1980.
105. Swain SL, Dialynas DP, Fitch FW, English M: Monoclonal antibody to L3T4 blocks the function of T cells specific for class 2 major histocompatibility complex antigens. J Immunol 132:1118-1123, 1984.
106. Terato K, Hasty KA, Cremer MA, et al: Collagen induced arthritis in mice. Localization of arthritogenic determinant to a fragment of type II collagen molecule. J Exp Med 162:637-646, 1985.
107. Theofilopoulos AN: The basis of autoimmunity: Part I: Mechanisms of aberrant self recognition. Immunol Today 16:90-98, 1995.
108. Townsend ARM, Ohlen C, Bastin J, et al: Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 340:443-448, 1989.
109. Von Boehmer H, Haas WH: H-2 restricted cytolytic and noncytolytic T cell clones: Isolation, specificity and functional analysis. Immunol Rev 54:27-56, 1981.
110. Wakabayashi T, Onoda H, Sugimoto H, et al: Not donor but recipient dendritic cells are involved in human renal rejection. Transplant Proc 25:856-858, 1993.
111. Warrens AN, Lombardi G, Lechler R: Presentation and recognition of major and minor histocompatibility antigens. Transplant Immunol 2:103-107, 1994.
112. Weaver CT, Unanue ER: The costimulatory function of antigen-presenting cells. Immunol Today 11:49-55, 1990.
113. Weber S, Traunecker A, Oliven F, Gerhard W, Karjalainen K: Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor. Nature 356:793-796, 1992.
114. Wilde DB, Marrack P, Kappler J, Dialynas DP, Fitch FW: Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J Immunol 131:2178-2183, 1983.
115. Zanelli E, Gonzalez-Gay MA, David CS: Could HLA-DRB1 be the protective locus in rheumatoid arthritis? Immunol Today 16:274-278, 1995.